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nusinersen ameliorates motor 
function and prevents motoneuron 
cajal body disassembly 
and abnormal poly(A) RnA 
distribution in a SMA mouse model
María t. Berciano1,4,5,8, Alba Puente‑Bedia2,8, Almudena Medina‑Samamé3, 
José C. Rodríguez‑Rey1,4, Jordi Calderó6, Miguel Lafarga3,4,5 & Olga Tapia4,5,7*
Spinal muscular atrophy (SMA) is a devastating autosomal recessive neuromuscular disease 
characterized by degeneration of spinal cord alpha motor neurons (αMNs). SMA is caused by the 
homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene, resulting in reduced 
expression of SMN protein, which leads to αMN degeneration and muscle atrophy. The majority 
of transcripts of a second gene (SMN2) generate an alternative spliced isoform that lacks exon 7 
and produces a truncated nonfunctional form of SMN. A major function of SMN is the biogenesis 
of spliceosomal snRNPs, which are essential components of the pre‑mRNA splicing machinery, 
the spliceosome. In recent years, new potential therapies have been developed to increase SMN 
levels, including treatment with antisense oligonucleotides (ASOs). The ASO‑nusinersen (Spinraza) 
promotes the inclusion of exon 7 in SMN2 transcripts and notably enhances the production of full‑
length SMN in mouse models of SMA. In this work, we used the intracerebroventricular injection of 
nusinersen in the SMN∆7 mouse model of SMA to evaluate the effects of this ASO on the behavior 
of Cajal bodies (CBs), nuclear structures involved in spliceosomal snRNP biogenesis, and the cellular 
distribution of polyadenylated mRNAs in αMNs. The administration of nusinersen at postnatal day (P) 
1 normalized SMN expression in the spinal cord but not in skeletal muscle, rescued the growth curve 
and improved motor behavior at P12 (late symptomatic stage). Importantly, this ASO recovered the 
number of canonical CBs in MNs, significantly reduced the abnormal accumulation of polyadenylated 
RNAs in nuclear granules, and normalized the expression of the pre‑mRNAs encoding chondrolectin 
and choline acetyltransferase, two key factors for αMN homeostasis. We propose that the splicing 
modulatory function of nusinersen in SMA αMN is mediated by the rescue of CB biogenesis, resulting 
in enhanced polyadenylated pre‑mRNA transcription and splicing and nuclear export of mature 
mRnAs for translation. our results support that the selective restoration of SMn expression in the 
spinal cord has a beneficial impact not only on αMNs but also on skeletal myofibers. However, the 
rescue of SMn expression in muscle appears to be necessary for the complete recovery of motor 
function.
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease that is considered the main 
genetic cause of infant mortality. SMA is caused by the homozygous loss or mutation of the survival of motor 
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neuron 1 (SMN1) gene, leading to reduced levels of full-length SMN protein. SMN depletion triggers the selective 
degeneration of lower alpha motor neurons (αMNs), resulting in preferential atrophy of the proximal skeletal 
muscles with weakness and muscle  paralysis1–3.
In addition to the SMN1 gene, humans ubiquitously express one or several copies of a closely related paralog 
gene called SMN2. This gene encodes a full-length SMN protein but presents one consistent difference, that is, 
the transition C to T (C6T) in exon 7. This change deactivates a splicing enhancer and introduces a splicing 
silencer, resulting in the exclusion of exon 7 in most SMN2  transcripts4,5. These transcripts are translated into 
a truncated SMN (SMNΔ7) protein that is rapidly ubiquitylated and degraded by the proteasome  system5–7. 
Although the expression of the SMN2 gene is residual under physiological conditions, the deletion or mutation 
of SMN1 confers the number of copies of SMN2 considerable importance in modifying the severity of SMA 
phenotypes. Thus, the most severe and frequent SMA is that of type I, which usually has two copies of the SMN2 
gene. Patients with type II or III SMA have a higher copy number of SMN28–11.
The functional full-length SMN protein homo-oligomerizes and forms a stable complex (SMN-complex) with 
Gemin2-8 and Unrip  proteins3,12. The SMN complex acts as a molecular chaperone to assist the cytoplasmic stage 
of the assembly of spliceosomal U snRNPs, which are essential splicing factors of the  spliceosome13,14. Linked 
to this function of the SMN complex, the Cajal body (CB) is particularly relevant, given its implication in the 
biogenesis of both spliceosomal U snRNPs and nucleolar  snoRNPs15–18. In particular, the enrichment of the CB 
in spliceosomal U snRNPs is consistent with the growing evidence of a spatial association of this organelle with 
certain transcriptionally active genomic loci of  snRNAs17,19–21. Moreover, the physical association of CBs with 
the dense fibrillar component of the nucleolus, the site of synthesis and early processing of pre-rRNAs provides 
a molecular link for a nucleolus-CB  interaction18,22–24.
In this context, recent studies from our laboratory have shown that reduced SMN levels in αMNs of a type I 
SMA patient and the SMN∆7 mouse model induce nuclear features of αMN degeneration, including depletion 
of canonical CBs, nucleolar stress and altered mRNA  processing25,26. The dysfunction of mRNA processing in 
this SMA mouse is also characterized by (i) the early and progressive accumulation of polyadenylated mRNAs 
in nuclear granules called PARGs (“poly(A) RNA granules”), (ii) the increase in intron-containing pre-mRNAs, 
and (iii) the disruption of the protein synthesis  machinery25–27. In fact, the dysfunction of RNA metabolism 
has enabled us to redefine the SMA as a RNA pathology, although it could also be considered a  spliceopathy28.
To explore whether normalizing SMN expression in SMN∆7 αMNs during the neonatal period, prior to 
αMN degeneration, prevents CB depletion and splicing alterations with nuclear retention of unspliced pre-
mRNAs in PARGs, we treated SMN∆7 mice with the antisense oligonucleotide (ASO) nusinersen (Spinraza). This 
2′-O-methoxyethyl (MOE)-modified ASO was designed to increase full-length SMN protein levels by promot-
ing the inclusion of exon 7 in SMN2 mRNAs. Nusinersen binds to a target site within intron 7, ≅ 10 nucleotides 
downstream of the 5′-splice site, known as ISS-N1 (intronic splicing silencer N1)29. This interaction displaces 
the splicing suppressor proteins hnRNP A1/A2 and enables spliceosomal U1 snRNPs to bind to the 5′-splice site, 
thereby promoting the inclusion of exon 7 in SMN2  transcripts29–35. Previous studies in mouse SMA models have 
demonstrated that nusinersen, when administered directly into the cerebrospinal fluid (CSF), prolongs animal 
survival and prevents αMN and skeletal muscle  pathology31,36,37.
Our results in SMN∆7 αMNs show that the intracerebroventricular (ICV) injection of nusinersen at the 
neonatal period (postnatal day [P] 1) (i) improves motor function, (ii) rescues the CB number, (iii) increases 
the expression of pre-mRNAs encoding chondrolectin (Chodl) and choline acetyltransferase (Chat), two key 
factors for αMN  homeostasis38, and (iv) reduces the nuclear retention of polyadenylated mRNAs into PARGs at 
the symptomatic P12 stage. These effects are accompanied by the restoration of the protein synthesis machinery, 
supporting an effective recovery of mRNA processing and translation.
Results
Treatment with ASO‑nusinersen (Spinraza) robustly rescues the growth curve, enhances 
motor function and dramatically reduces αMN loss. Based on previous studies from our laboratory, 
we have established two temporary windows that demarcate the clinical evolution of SMNΔ7 mice: (i) the pre-
clinical phase (from P0 to P6) and (ii) the clinical phase (from P7 to P12), when the clinical symptoms appear 
and progress, commonly leading to the death of mice between P12 and P14.
The ICV administration of nusinersen (Fig. 1A) at P1 was well tolerated with no obvious signs of toxicity or 
drug-related death. First, we studied the clinical evolution of SMN∆7 mice treated or not treated with nusin-
ersen. We evaluated the growth curve of mice by performing daily measurement of the body weight from P1 to 
P12 (Fig. 1C). We noticed that nusinersen treatment had a highly significant impact on body weight gain with 
a growth curve comparable to that of vehicle-treated WT (hereafter referred to as WT) mice from P6 to P12 
(Fig. 1B–D). In fact, nusinersen-treated SMN∆7 mice weighed approximately twice as much as the vehicle-treated 
mice (hereafter referred to as SMN∆7) at P12 (Fig. 1B–D). On the other hand, nonsignificant differences in body 
weight were found between WT animals treated with vehicle and nusinersen, indicating that the administration 
of this ASO does not modify body weight under physiological conditions (“body weight follow-up × genotype”: 
 F(4,40) = 84.23, p < 0.0001; “body weight follow-up × nusinersen treatment”:  F(4,40) = 57.64, p < 0.0001).
Next, we investigated whether nusinersen treatment improves motor functions in SMN∆7 mice by using the 
righting reflex test. This test evaluates the overall muscle strength and motor coordination, which are severely 
affected in SMA mice due to weakness of the limb and trunk muscles. The test assesses the time taken for the 
mouse placed on its back to right itself through 180° to a maximum of 30 s39. Whereas the SMNΔ7 mice did not 
acquire the righting reflex during the neonatal period studied (P1-P12) (Fig. 1E), both WT mice and nusinersen-
treated SMNΔ7 mice acquired this motor reflex as early as P3, although the latter showed a temporary delay in 
the completion of the test (Fig. 1E) (“righting reflex follow-up × genotype”:  F(3,39) = 14.85, p < 0.0001; “righting 
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Figure 1.  (A) Scheme illustrating the intrathecal injection point of the ASO-nusinersen (Spinraza). (B,C) 
Images showing differences in body size between WT and SMNΔ7 mice (B) and WT and nusinersen-treated 
SMNΔ7 mice (C) at P12. (D) Comparative analysis of body weight (mean ± SD) among WT, SMNΔ7 and 
nusinersen-treated SMNΔ7 mice from P0 to P12 (n = 8 mice per group). #p < 0.01, ###p < 0.0001: WT vs. 
SMN∆7; ***p < 0.0001: vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7. (E) Response to righting 
motor reflex acquisition (mean ± SD) at the indicated postnatal periods. Note how nusinersen treatment 
ameliorates the motor response in SMNΔ7 mice when compared to untreated SMNΔ7 mice (n = 8 mice per 
group). ###p < 0.0001: WT vs. SMN∆7; ***p < 0.0001: vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7. 
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reflex follow-up × nusinersen treatment”:  F(3,39) = 72.77, p < 0.0001). Moreover, whereas SMNΔ7 mice exhibited 
very severe muscular atrophy, which affects the ability of moving, nusinersen-treated SMNΔ7 mice exhibited 
moderate hindlimb atrophy and preserved ambulation capacity; however, moderate hindlimb paresis was notice-
able in these animals compared to WT mice (see Supplementary Video S1).
To determine whether the clinical improvement of nusinersen-treated SMNΔ7 mice was produced by nor-
malizing SMN levels in the spinal cord, we performed a western blot analysis in tissue lysates at P12. The results 
in SMNΔ7 mice showed that nusinersen treatment increased SMN expression by 2.5 times in the spinal cord 
compared with untreated animals. The increase reached approximately 70% of SMN levels from WT samples 
(Fig. 1O). Next, we investigated whether nusinersen treatment modified SMN protein levels in muscle, a periph-
eral tissue essentially involved in SMA  pathogenesis40,41. Western blot analysis of the tibialis anterior (TA) muscle 
lysates revealed that the neonatal ICV delivery of nusinersen in SMNΔ7 mice did not increase SMN expression 
in muscle at P12 (Fig. 1O). This result suggests that the therapeutic agent did not cross the blood–brain barrier 
in neonatal mice, and consequently, the beneficial clinical effect of nusinersen treatment should be mainly due 
to increased SMN expression in the spinal cord. Consistent with this view, SMN immunolabeling of dissociated 
αMNs showed that the staining pattern in nusinersen-treated SMNΔ7 neurons was similar to that found in WT 
neurons. SMN was diffusely distributed in the cytoplasm with a moderate intensity of fluorescent signal. In the 
nucleus SMN was specifically concentrated in CBs (Fig. 1F,H). Interestingly, αMNs from SMNΔ7 mice exhibited 
a notably weak cytoplasmic signal of SMN, and CBs were rarely observed (Fig. 1G).
To further understand the effects of nusinersen treatment on the survival of SMNΔ7 αMNs, we performed 
a quantitative analysis on spinal cord cryosections (lumbosacral region) immunostained for ChAT, a marker of 
αMNs40,42. As expected, nusinersen treatment preserved the population of αMNs in the anterior horn (Fig. 1I,K). 
Thus, no significant differences in the mean number of αMNs per section were found between WT mice and 
nusinersen-treated SMNΔ7 animals (Fig. 1P). In contrast, differences were significant when these two groups 
were compared with SMNΔ7 mice, which had an overt depletion of αMNs (Fig. 1J–K,P).
Since nusinersen treatment prevents αMN death and presumably the formation and maintenance of the neu-
romuscular junction, we next investigated whether this ASO can prevent muscle atrophy induced by neurogenic 
myopathy in SMNΔ7 mice. We estimated the myofiber size distribution on cross-cryosections of the TA muscle 
using the histochemical enzymatic assay for succinate dehydrogenase (SDH), a marker of mitochondrial oxidative 
 activity40. Interestingly, despite the reduced SMN expression in the muscle of nusinersen-treated SMNΔ7 mice, 
nonsignificant differences in myofiber diameter were found between WT mice and nusinersen-treated SMNΔ7 
mice at P12 (Fig. 1Q). However, a significant reduction in the myofiber diameter was detected in SMNΔ7 mice 
compared with nusinersen-treated mice (Fig. 1Q). Moreover, SDH histochemistry revealed that both WT and 
nusinersen-treated SMNΔ7 myofibers exhibited a staining checkboard pattern of a mixed muscle with a similar 
proportion of myofibers whose SDH oxidative activity corresponded to type 1, 2A and 2X (Fig. 1L,N). In contrast, 
vehicle-treated SMNΔ7 myofibers were clearly atrophic with reduced diameter and an oxidative intensity of stain 
predominantly corresponding to aerobic type 1 myofibers (Fig. 1M,Q). It should be noted that the administration 
of nusinersen in WT mice did not change the SDH pattern detected in vehicle-treated WT mice (data not shown).
Nusinersen treatment prevents the disruption and loss of canonical Cajal bodies (CBs) in αMNs 
of the SMA mouse. The CB is a transcription-dependent nuclear organelle whose number and size accom-
modate the cellular demands of pre-mRNA  splicing16,18. Consistent with this notion, our previous studies in 
αMNs from an SMA patient and the SMNΔ7 mouse have shown that the αMN degeneration caused by SMN 
In C,D, data were analyzed by a one-way ANOVA, followed by the Bonferroni post hoc test using SPSS. 
(F–H) Immunodetection of SMN reveals that nusinersen treatment rescues the typical SMN staining pattern 
in WT αMNs, which appears diffuse in the cytoplasm and concentrated in CBs (F,H). In contrast, αMNs 
from the untreated SMNΔ7 mouse exhibit a very weak cytoplasmic SMN signal and CB depletion (G). (I–K) 
Immunodetection of ChAT in the anterior horn of spinal cord showing how nusinersen treatment increases 
αMN number in the SMNΔ7 mouse compared with the untreated SMNΔ7 animals. (L–N) SDH histochemical 
staining of transverse cryosections of the TA muscle from WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice 
at P12. In SMNΔ7 mice, this treatment rescues the myofiber phenotype found in WT muscle with a similar 
distribution of type 1, 2A and 2X myofibers (L,N). Note that the nusinersen-untreated SMNΔ7 muscle is 
preferentially composed of smaller type 1 myofibers (M). (O) Western blot analysis of SMN protein levels in 
whole spinal cord and skeletal muscle lysates at P12. Note the reduction in SMN levels in the spinal cord and 
muscle of the SMNΔ7 mouse and the recovery of SMN expression in the spinal cord but not in the muscle upon 
nusinersen treatment. SMN bands were normalized to lamin, and the relative expression levels of SMN were 
calculated using ImageJ. Full-length blots are presented in Supplementary Information. (P) Quantitative analysis 
of the number of αMNs (mean ± SD) in transverse cryosections of the spinal cord immunostained for ChAT. 
αMN counts were performed on the hemispinal cords of WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice 
at P12. *p < 0.05 when WT and SMN∆7 or vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7 mice were 
compared (n = 4 per group, Student’s t test analysis was performed using GraphPad). (Q) Quantitative analysis 
of the myofiber diameter (mean ± SD) on transverse cryosections of the TA muscle histochemically stained for 
SDH detection. Measurements were performed in WT, SMNΔ7 and nusinersen-treated SMNΔ7 mouse muscles 
at P12. **p < 0.005 when WT and SMN∆7 or vehicle-treated SMN∆7 vs. nusinersen-treated SMN∆7 mice were 
compared (n = 4 per group, Student’s t test analysis was performed using GraphPad). Scale bars: 10 µm (F–H), 
30 µm (I–K) and 5 µm (L–N).
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deficiency includes an early depletion of canonical CBs and relocalization of coilin as perinucleolar caps and/or 
within the  nucleolus18,25. Based on this observation, we considered that the disruption of CBs is an early nuclear 
sign of αMN degeneration in SMA.
Having established that nusinersen treatment preserves the normal population of αMNs and increases SMN 
protein levels in the spinal cord, we next investigated whether this agent rescues the formation and assembly of 
canonical CBs in SMNΔ7 αMNs. Double immunolabeling for coilin and SMN revealed the typical cytoplasmic 
distribution of SMN and the regular presence of canonical CBs, which concentrate coilin and  SMN16,18, in both 
WT and nusinersen-treated SMNΔ7 αMNs (Fig. 2A,C,D,F). Moreover, these canonical CBs showed a preferential 
association with the nucleolus (Fig. 2D,F), as previously reported in other mammalian  neurons18,22. In contrast, 
the reduced cytoplasmic SMN staining observed in SMNΔ7 αMNs was accompanied by depletion of canonical 
CBs and formation of coilin-positive perinucleolar caps, where SMN was not or only slightly detected (Fig. 2B,E). 
Plots of linear profiles of coilin and SMN fluorescence intensity signals confirmed the colocalization of both 
molecules in canonical CBs and the absence of SMN in the perinucleolar caps (see Supplementary Fig. S2, A–C).
The neuroprotective effect of nusinersen treatment on SMNΔ7 αMNs was validated by a quantitative analysis 
of the mean number of CBs per nucleus in neuronal dissociates coimmunostained for coilin and SMN. Nonsig-
nificant differences in the mean number of canonical CBs were detected between WT and nusinersen-treated 
SMNΔ7 αMNs at P12 (n = 4; 2.44 ± 0.34 vs. 2.94 ± 0.54; p = 0.18) (Fig. 2A,C). However, in the neurodegenerative 
phase of SMNΔ7 αMNs (P12), CB number was dramatically reduced compared with WT αMNs (n = 4; 0.08 ± 0.28 
in SMNΔ7, vs. 2.44 ± 0.34 in WT; p = 0.00009) (Fig. 2A,B).
To further characterize the molecular organization of CBs, we performed double immunolabeling for coilin 
in combination with either TMG-cap, a marker of spliceosomal snRNPs that recognizes the 5′ end of  snRNAs43, 
or fibrillarin, a nucleolar snoRNP shared with the  CB18,22. As expected, both TMG-cap and fibrillarin signals 
colocalized with coilin in the CBs of WT αMNs and nusinersen-treated SMNΔ7 αMNs (Fig. 2G,I,J,L; Supple-
mentary Fig. S2D, F, G and I), indicating that these nuclear bodies are canonical functional CBs that concentrate 
splicing factors and snoRNPs in addition to coilin and  SMN16,44. In contrast, perinucleolar caps of SMNΔ7 αMNs 
lacked a TMG-cap signal and had weak staining for fibrillarin (Fig. 2H,K).
Finally, it is noteworthy that Gems, coilin-negative and SMN-positive nuclear  bodies45,46 are conspicuously 
absent in αMNs in all experimental groups studied.
nusinersen treatment rescues the transcription rate of Chodl and ChAT pre‑mRNAs. Previous 
studies have demonstrated widespread defects in transcription and pre-mRNA splicing of essential genes for 
αMN homeostasis in cellular and animal models of  SMA27,47–51. Among these genes, Chodl (chondrolectin) and 
ChAT (choline acetyltransferase) are highly expressed in αMNs, playing crucial functions in motor axon growth 
and neurotransmission,  respectively38,52. Moreover, Chodl and ChAT are major gene products with dysregulated 
expression in SMA mouse αMNs27,38.
To determine whether nusinersen treatment is able to rescue the transcription rate of Chodl and ChAT, we 
analyzed the expression levels of both pre-mRNAs by qRT-PCR in spinal cord RNA extracts at P12. We found a 
significant reduction in Chodl and ChAT pre-mRNAs in SMNΔ7 samples compared with WT samples (Fig. 3A). 
Remarkably, nusinersen treatment in SMNΔ7 mice rescued the transcription rates of both genes, which reached 
pre-mRNA levels comparable to WT ones (Fig. 3A).
Nusinersen treatment normalizes the distribution of the protein synthesis machinery and pol‑
yadenylated mRNAs in SMNΔ7 mice. Our group and others have previously shown a severe perturba-
tion of the protein synthesis machinery with a remarkable nuclear and cytoplasmic redistribution of polyade-
nylated RNAs and chromatolysis in αMNs of SMA mouse  models26,27,53. On this basis, we investigated whether 
nusinersen treatment is able to prevent this severe perturbation of neuronal homeostasis in SMNΔ7 αMNs. 
Cytochemical staining of RNA-rich structures with propidium iodide revealed prominent Nissl bodies (cyto-
plasmic areas enriched in rough endoplasmic reticulum and free  polyribosomes54) distributed throughout the 
cytoplasm in both WT and nusinersen-treated SMNΔ7 αMNs (Fig. 3C,E). In contrast, most αMNs from SMNΔ7 
mice exhibited different degrees of disruption of Nissl bodies, particularly central chromatolysis (Fig. 3D).
Next, we analyzed whether nusinersen treatment preserves the normal distribution of poly(A) RNAs, which 
include all mRNAs with the exception of histone mRNAs, as an indicator of proper nuclear mRNA processing 
and export to the cytoplasm. In situ hybridization with the poly-dT probe revealed that poly(A) RNA appeared 
diffusely distributed throughout the nucleus (excluding the nucleolus), highly concentrated in nuclear speckles 
and accumulated in extensive cytoplasmic areas of WT αMNs (Fig. 3F,I). In contrast, SMNΔ7 αMNs displayed 
a prominent nuclear aggregation of poly(A) RNAs in PARGs (Fig. 3G,J), round sharply defined bodies previ-
ously reported in mouse SMA αMNs and other neurons under stress  conditions27,55,56. In addition, we found a 
cytoplasmic reduction in the poly(A) RNA hybridization signal, suggesting a decreased availability of mRNA 
for translation (Fig. 3G,J). Interestingly, SMNΔ7 αMNs treated with nusinersen tended to normalize the nuclear 
and cytoplasmic distribution of polyadenylated mRNAs observed in WT αMNs (Fig. 3H,K). Furthermore, the 
proportion of αMNs carrying PARGs was significantly reduced in nusinersen-treated SMNΔ7 mice compared to 
SMNΔ7 animals (Fig. 3B). Since the formation of PARGs begins during the perinatal  period27, probably before 
drug administration, we assume that the reduced number of PARGs found in nusinersen-treated SMNΔ7 αMNs 
is a remnant of the fetal or perinatal stage. We suggest that the nuclear retention of poly(A) RNA into PARGs 
can be a neuroprotective mechanism to prevent the nuclear export and translation of unprocessed or aberrant 
polyadenylated mRNAs.
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Figure 2.  (A–F) Confocal images of dissociated αMNs from WT (A,D), SMN∆7 (B,E) and nusinersen-
treated SMN∆7 mice (C,F) double immunolabeled for coilin (red) and SMN (green). Note that coilin and 
SMN colocalize in canonical CBs from WT and nusinersen-SMNΔ7 αMNs (D,F), whereas coilin-positive and 
SMN-negative perinucleolar caps are detected in αMNs from the vehicle-treated SMNΔ7 mouse. (G–L) Double 
immunolabeling for coilin and TMG-cap (G–I) or fibrillarin (J–L) in αMNs from WT, SMNΔ7 and nusinersen-
treated SMNΔ7 mice. Coilin colocalizes with both TMG-cap and fibrillarin in canonical CBs from WT and 
nusinersen-treated SMNΔ7 αMNs (G,I,J,L). In contrast, the perinucleolar caps of SMNΔ7 αMNs are free from 
the splicing factor marker TMG-cap (H) and exhibit a weak fibrillarin signal (K). Scale bars: 20 µm (A–C), 5 µm 
(D–I) and 2.5 µm (J–L).
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Figure 3.  (A) RT-PCR analysis of the expression of Chodl and ChAT pre-mRNAs in whole spinal cord RNA 
extracts from WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice at P12. Bars represent the mean ± SD, *p < 0.05 
and ***p < 0.0005 (n = 4 mice per group, Student’s t test analysis was performed using GraphPad). (B) The mean 
percentages of αMNs with PARGs were 1.38% in WT mice and 35.73% in SMN∆7 mice. Nusinersen treatment 
in SMN∆7 mice significantly reduced the proportion of αMNs with PARGs to 12.04%. p values of WT vs. 
SMN∆7 αMNs: 1.78 × 10–6 (***p < 0.0005); SMN∆7 vs. nusinersen-treated αMNs: 2.8 × 10–6 (***p < 0.0005); 
and WT vs. nusinersen-treated SMN∆7: 0.0046 (**p < 0.005) (Student’s t test analysis was performed using 
GraphPad). (C–E) Dissociated spinal cord αMNs from WT, SMNΔ7 and nusinersen-treated SMNΔ7 mice 
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Discussion
It is well established that αMNs are the main physiopathological cellular targets of SMA, although increasing 
evidence has revealed the primary importance of other peripheral  tissues41,57,58. Degeneration of αMNs leads to 
severe muscular atrophy by denervation, muscle paralysis and premature death by respiratory failure in type I 
SMA, the most severe form of the disease.
In our previous studies in the SMNΔ7 mouse model of SMA, we observed that SMN depletion in αMNs 
during the symptomatic postnatal stage severely impacts nuclear compartments involved in pre-rRNA and 
pre-mRNA  processing26. Moreover, polyadenylated mRNAs are aggregated in PARGs, reflecting an alteration of 
mRNA splicing with increased intron retention, abnormal accumulation of incorrectly processed mRNAs and 
inhibition of the nuclear export of mature  mRNAs27. This neuronal dysfunction leads to a neurodegenerative 
process, which is characterized by reduced availability of mature mRNAs for translation, progressive disruption 
of the protein synthesis machinery and, ultimately, neuronal  death26,27,53.
In this study, we demonstrate that the therapeutic outcome of the ICV administration of nusinersen (Spin-
raza) in the SMNΔ7 mouse model of type I SMA is mediated by the selective restoration of SMN levels in the 
spinal cord but not in muscle. Nusinersen treatment in neonatal SMNΔ7 mice normalizes the growth curve and 
improves motor function at the late symptomatic stage (P12). These effects are mediated by preserving the normal 
population of αMNs, as well as the nuclear organization of mRNA processing compartments and the protein 
synthesis machinery. Consistent with these findings, previous studies in mouse SMA models have demonstrated 
that nusinersen, when administered directly into the CSF, prolongs animal survival and prevents αMN and skel-
etal muscle  pathology31,36,37. However, a recent study using the systemic administration of ASO10-27 in SMA 
mice supports that peripheral tissues play an essential role in SMA  pathology41. The authors indicate that the 
increase in SMN exclusively in peripheral tissues compensates for its deficiency in the spinal cord and preserves 
αMNs. In our study, the improvements in body weight, motor function and survival in SMN∆7 mice treated with 
nusinersen were associated with a notable increase in SMN levels in the spinal cord but not in the TA muscle, 
which exhibited reduced SMN levels, similar to those detected in untreated SMN∆7 mice. Although a fraction 
of nusinersen injected into cerebral ventricles may be cleared with CSF into the blood and influence peripheral 
tissues, our results and those from other  authors59 support that the increase in SMN in the spinal cord is required 
for the rescue of αMN and skeletal myofiber homeostasis. In fact, we observed that both the skeletal myofiber 
size distribution and the SDH oxidative staining pattern of myofibers are rescued, despite having reduced SMN 
levels in muscle. However, the relative importance of SMN restoration in spinal cord versus peripheral tissues 
in the therapeutic outcome reported in separate studies may be notably influenced by differences in transgenic 
mouse models of SMA and treatment protocols with ASO.
Consistent with the essential role of nusinersen in the splicing regulation of the SMN2 gene, promoting the 
inclusion of exon 7 in the SMN2 mRNAs and their translation in full-length SMN  protein30–32,34,60, we detected 
a recovery in the number and molecular composition of CBs. This neuroprotective mechanism, mediated by 
the increased expression of SMN in αMNs, can promote the molecular assembly of canonical CBs, which are 
enriched in coilin, SMN and spliceosomal  snRNPs15,16,43. CBs are transcription-dependent nuclear organelles 
involved in spliceosomal snRNP biogenesis required for pre-mRNA  splicing15,16,61. Depletion of CBs and coilin 
relocation in the form of perinucleolar caps or within the nucleolus are reliable early signs of neuronal dysfunc-
tion in many neurodegenerative disorders, including  SMA18,25,26,62. It is noteworthy that snRNPs are essential 
components of the spliceosome, the macromolecular machine for pre-mRNA  splicing14, and their biogenesis is 
considerably more efficient in CBs than in the  nucleoplasm63. In fact, depletion of CBs in cells derived from SMA 
patients correlates with reduced U4/U6-U5 tri-snRNP assembly, a key maturation step of spliceosomal snRNPs, 
and with splicing  alterations47,64. A recent study reported an increase in the number of Gems (SMN-positive 
and coilin- and snRNP-negative nuclear bodies of unknown  function45,46) in αMNs following the subcutaneous 
administration of ASO10-27 in a mouse model of  SMA41. However, in our study, we have never observed Gems 
but canonical CBs induced by nusinersen treatment in SMA mice.
In nusinersen-treated SMNΔ7 mice, the transcription rate activation of Chodl and ChAT, two genes dys-
regulated in SMA that are essential for αMN  survival38,52, is consistent with the increase in CBs, whose numbers 
must be accommodated to the neuronal demand for pre-mRNA  processing44. In this context, it was also note-
worthy that nusinersen treatment in SMNΔ7 mice also rescued the normal organization of the protein synthesis 
machinery (Nissl bodies) and substantially recovered the nuclear and cytoplasmic compartmentalization of 
polyadenylated mRNAs. It is well established that all mRNAs, except for histone mRNAs, are polyadenylated in 
the nucleus, and the poly(A) tail is necessary for efficient mRNA export and  translation65. The regulation of the 
nuclear and cytoplasmic compartmented transcriptomes is essential for cell homeostasis. Indeed, in this study 
and  previously27, we have demonstrated the nuclear accumulation of polyadenylated RNAs into PARGs, which is 
at P12 stained with propidium iodide (PI) to demonstrate the RNA-rich nucleolus and protein synthesis 
machinery (Nissl substance). Note the rescue of prominent Nissl bodies in nusinersen-treated SMNΔ7 αMNs 
(E) and the central chromatolysis in untreated SMNΔ7 αMNs (D). (F–H) FISH for poly(A) RNAs in WT, 
SMNΔ7 and nusinersen-treated SMNΔ7 αMNs at P12. A similar pattern of poly(A) RNA hybridization signal 
was observed in WT and nusinersen-treated SMNΔ7 αMNs: diffuse in the nucleus, excluding the nucleolus, 
concentrated in nuclear speckles of splicing factors and diffuse in the cytoplasm (F,H,I,K). Note the abundance 
of nuclear poly(A) RNA-positive granules (PARGs) in numerous SMNΔ7 αMNs, which was accompanied by 
a substantial reduction of the hybridization signal in the cytoplasm (G,J). PARGs were occasionally found in 
nusinersen-treated SMNΔ7 αMNs (H, inset). Scale bars: 15 µm (C–E), 25 µm (F–H) and 5 µm (I–K).
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associated with intron retention. Nuclear retention of polyadenylated mRNAs may prevent the nuclear export of 
unspliced or inappropriately expressed transcripts and attenuate translation and energy consumption to maintain 
energy homeostasis under stress  conditions27,66. Moreover, nuclear retention of polyadenylated mRNAs may be 
linked to defective snRNP biogenesis in CBs. In this sense, a recent  study67 reported that the inhibition of U4 
snRNP biogenesis, a key component for U4/U6-U5 tri-snRNP assembly in  CBs68, results in the abnormal nuclear 
accumulation of polyadenylated mRNAs. Importantly, the ICV administration of nusinersen in SMN∆7 mice 
substantially reduced the formation of PARGs and restored the nuclear and cytoplasmic compartmentalization of 
polyadenylated mRNAs in αMNs. This neuronal response is consistent with a substantial recovery of CB number 
and pre-mRNA processing and export of mature polyadenylated mRNAs for their translation.
In conclusion, the nusinersen (Spinraza)-dependent rescue of the (i) molecular assembly of canonical CBs, 
(ii) expression of Chodl and ChAT primary transcripts, (iii) nuclear and cytoplasmic distribution of polyade-
nylated mRNAs, and (iv) organization of protein synthesis machinery in αMNs of the SMNΔ7 mouse appears 
to be essential for maintaining neuronal homeostasis and survival. The increase in SMN expression in the spinal 
cord partially prevents the severe SMA myopathy induced by αMN degeneration. We suggest that the incomplete 
recovery of neuromuscular performance in nusinersen-treated SMNΔ7 mice with moderate hindlimb paresis 
may result from reduced SMN expression in muscle. Further studies will be addressed to investigate the potential 
role of nusinersen treatment on skeletal myofibers, particularly on the focal disruption of the sarcomere archi-
tecture and actin dynamics observed in the SMNΔ7 mice (our unpublished results). In this vein, the combined 
use of subcutaneous and ICV administration of nusinersen may improve the therapeutic effects of this drug in 
SMA  myopathy41.
Materials and methods
Animals. Smn+/−;SMN2+/+;SMN∆7+/+, heterozygous knockouts for mouse Smn (FVB. Cg-
Tg[SMN2*delta7]4299Ahmb Tg[SMN2]89Ahmb Smn1tm1Msd/J, stock number 005025), which were pur-
chased from the Jackson Laboratory (Sacramento, USA), were crossed to generate Smn−/−;SMN2+/+;SMN∆7+/+ 
(SMN∆7) mice and Smn+/+;SMN2+/+;SMN∆7+/+ mice that were wild-type for Smn (WT). SMN∆7 mice exhibit a 
severe postnatal SMA phenotype with a mean lifespan of approximately 2 weeks69,70. Animal care and handling 
were performed in accordance with the Spanish legislation (Spanish Royal Decree 53/2013 BOE) and the guide-
lines of the European Commission for the Accommodation and Care of Laboratory Animals (revised in Appen-
dix A of the Council Directive 2010/63/UE). The experimental plan was approved by the Ethics Committee of 
the University of Cantabria and the Committee for Animal Care and Use of the University of Lleida. On P0, the 
identification of WT and SMN∆7 mice performed by genotyping with PCR. DNA was extracted from the tail, as 
previously  described69. Age-matched WT littermates of mutant animals were used as controls.
To investigate the effects of nusinersen (Spinraza) treatment in the αMNs of SMN∆7 mice, we used 32 ani-
mals (16 WT mice and 16 SMN∆7 mice) that were divided into four groups. WT and SMN∆7 mice were treated 
with 10 µl of Spinraza (Biogen) at a dose of 6.5 mg/kg (nusinersen group), or with 10 µl of a 0.9% saline solution 
(vehicle group). Spinraza or the vehicle was injected at the day of birth (P0) via ICV at the precise point indicated 
in Fig. 1A using a 10-µl syringe and a custom 33-gauge needle (Hamilton), as described  previously41. All mice 
were sacrificed at the late symptomatic neurodegenerative stage (P12)26,27.
Motor righting reflex test. To analyze the effect of nusinersen treatment on motor functions, we used the 
surface righting test (righting reflex), according to the protocol of Feather-Schussler and  Ferguson39. Briefly, this 
test assesses the motor capacity such that a mouse pup can stand up from a supine position. The average age for 
the rodent straightening reflex to appear is P5. As this test is a reflex, there is no learning component, and it can 
be repeated throughout the period of experimentation. This test consists of placing the pups face up on a cotton 
sheet or bench pad and keeping them in this position for 5 s. The pups are then released, and the time it takes to 
return to the prone position is recorded, as well as the direction of the correction (left or right). A total of 1 min 
is given for each test, if necessary. The test is repeated for a total of three trials.
Succinate dehydrogenase (SDH) assay. To investigate the effect of the ICV administration of nusin-
ersen on the phenotype type of TA muscle myofibers in the SMNΔ7 mouse, we used the histochemical SDH 
assay, a specific mitochondrial marker of myofiber oxidative activity. Thus, most SDH-positive myofibers corre-
spond to small type 1 myofibers, which have slow contraction and high aerobic metabolism. Less SDH-positive 
myofibers of type 2X of greater caliber are associated with faster contraction and more anaerobic muscle. Finally, 
type 2A myofibers have an intermediate signal and activity between type 1 and 2X  myofibers71. Briefly, transverse 
cryosections were incubated in an SDH reaction mixture (1.5 mM nitroblue tetrazolium, 5 mM EDTA, 48 mM 
succinic acid, 0.75 mM sodium azide, 30 mM methyl-phenylmethyl sulfate, and phosphate buffered pH 7). Dur-
ing the electron transfer from succinic acid to nitroblue tetrazolium by SDH, a color change occurs, the rate of 
which represents SDH activity. As controls, we used cryosections incubated in a medium lacking succinic acid. 
Then, the samples were air-dried and mounted, and images were captured with a microscope (Zeiss, Axioscop 
Plus) using 40 × or 63 × oil objectives. The morphometric analysis of myofiber diameter was performed on 
transversal cryosections of the TA muscle stained with the histochemical SDH assay. The measurement of the 
diameter of each myofiber in the field was performed on randomly collected microscope images using a 40 × 
objective and ImageJ software (National Institutes of Health). At least 100 myofibers per animal (n = 3, WT; n = 3, 
SMN∆7; and n = 3, nusinersen-treated SMN∆7 mice) were measured.
Immunofluorescence and confocal microscopy. For immunofluorescence analysis of αMNs at P12, 
4 mice per group (WT, SMN∆7 and nusinersen-treated SMN∆7 mice) were fixed by perfusion with 3.7% para-
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formaldehyde (freshly prepared) in phosphate-buffered saline (PBS) under deep anesthesia with pentobarbital 
(50 mg/kg). The spinal cords were rapidly dissected, removed, postfixed for 6 h and washed in PBS. Transverse 
sections (160-µm thick) of the spinal cord were obtained with a vibratome, and small tissue fragments from the 
anterior horn were dissected out. The samples were transferred to a drop of PBS on a positively charged slide 
(Superfrost Plus, Thermo Scientific, Germany), and squash preparations of dissociated MNs were generated fol-
lowing the previously reported  procedure43.
For muscle, tissue fragments of the TA were pinned to cork, immersed in ice-cold relaxing buffer (100 mM 
NaCl, 2 mM KCl, 2 mM  MgCl2, 6 mM  K3PO4, 1 mM EGTA, and 0.1% glucose; pH 7.0) and relaxed at 4 °C until 
fixed in 3.7%  paraformaldehyde72. Muscle fragments were cryoprotected in 15% and 30% sucrose in PBS (phos-
phate saline buffer: 137 mM NaCl, 2.7 mM KCl, 8 mM  Na2HPO4, and 2 mM  KH2PO4; pH 7.4) until they sank, 
embedded in Tissue-Tek OCT Compound (Sakura FineTek USA), and frozen on a chilled metal block in dry ice. 
Cryosections measuring 8 μm in thickness were mounted on SuperFrost slides and stored at − 80 °C until use.
For immunofluorescence, all samples were processed as described in Pena et al.43. Briefly, samples were 
treated with 0.5% Triton X-100 for 45 min and incubated for 3 h with the primary antibody containing at room 
temperature. Specific secondary antibody conjugated with FITC, Texas Red or Cy3, or Cy5 (diluted 1:75, Jackson, 
USA) were used. Some samples were counterstained with propidium iodide (PI) or Phalloidin-FITC. The slides 
were mounted with ProLong Anti-Fading Medium (Invitrogen).
We used an LSM510 (Zeiss, Germany) laser scanning microscope using a 63 × oil (1.4 NA) objective. To avoid 
overlapping signals, images were obtained by sequential excitation at 488 nm and 543 nm. The fluorescence pro-
files of confocal intensity signals across a line shown in Fig. S2 were generated using confocal images of double 
immunolabeled samples. Images were processed using Adobe Photoshop CS6 software.
The following primary antibodies were used for immunofluorescence: mouse monoclonal anti-SMN (diluted 
1:100, catalog no. 610646, BD Transduction Laboratories, USA); mouse monoclonal anti-TMG-cap (NA02A, 
Oncogene, USA); mouse monoclonal anti-fibrillarin (diluted 1:100, catalog no. ab4566, Abcam, USA); rabbit 
polyclonal anti-coilin (1:500, 204.10, Prof. A. Lamond, Dundee, UK); and goat polyclonal anti-choline acetyl-
transferase (ChAT) (1:200, AB144P, Millipore, MA, USA).
In situ hybridization and quantification. Fluorescence in  situ hybridization (FISH) was performed 
according to the protocol described by Narcís et al.27. Preparations of MNs were permeabilized with TBS-E-SDS 
for 15 min at 37 °C, washed three times in 6 × SSPE-0.1% Tween 20 for 15 min, and incubated with the probe 
containing tRNA for 3 h at 42  °C in a humidified chamber. An oligo(dT)(50)-mer, 5′-end-labeled with biotin 
(MWG-Biotech, Germany), was used as a probe for fluorescence in situ hybridization (FISH) to poly(A) RNA. 
The hybridization mixture contained 80 ng of oligo dT(50), 2 × SSC, 1 mg/ml tRNA, 10% dextran sulfate and 
25% formamide. After hybridization, preparations of MNs were washed in 6 × SSC for 15 min and then washed 
in 4 × SSC-0.1% Tween 20 for 15 min at room temperature. The hybridization signal was detected with FITC-
avidin for 30 min. All samples were mounted with Vectashield (Vector, USA).
The quantitative analysis of the proportion of SMN∆7 αMNs containing PARGs was performed in squash 
preparations processed for FISH with the poly(dT) probe. The proportion of neurons containing these granules 
was estimated by direct examination of the different focal planes throughout neuronal nuclei using a 40 × objec-
tive. Quantification was performed on at least 100 αMNs from WT (n = 4), SMN∆7 (n = 4) and nusinersen-treated 
SMN∆7 (n = 4) mice.
qRT‑PCR for relative gene expression analysis. For qRT-PCR, we used WT (n = 4), SMN∆7 (n = 4) 
and nusinersen-treated SMN∆7 (n = 4) mice. Mice were decapitated after being anesthetized, and the lumbar 
spinal cord was quickly removed and frozen in liquid nitrogen. RNA was isolated with TRIzol following the 
manufacturer’s instructions (Invitrogen, Carlsbad) and purified with the RNeasy kit (Qiagen, Hilden, Germany).
According to our laboratory  protocols27, 1 μg of RNA was reverse-transcribed to first-strand cDNA utilizing 
a High Capacity cDNA Reverse Transcription Kit (Life Technologies) using random hexamers as primers. The 
expression of the mRNA candidates ChAT and Chodl was determined by qRT-PCR using gene-specific SYBR 
Green-based primers (Invitrogen). The threshold cycle (Ct) for each well was determined and the results were 
normalized to Gapdh mRNA. Relative gene expression was calculated according to the 2-(ΔΔCt)  equation73. Each 
value in this work represents the mean ± SD of independent samples obtained under the same conditions and 
compared to two replicated qRT-PCR analyses. The SYBR Green-based specific primers for murine pre-RNAs 
analyzed were as follows: for the pre-mRNA of ChAT 5′-CTT GGG GCC AGT CTG ATA GC-3′ and 5′-GGA CAC 
ATG GCT AGA AGG GG-3′ and for the pre-mRNA of Chodl 5′-GCT GTT GTC TCC CGC ATC TT-3′ and 5′-AAG 
TGG AAG CGT TTG GGA TT-3′.
SDS‑PAGE and immunoblotting. Analysis of the level of SMN protein were performed according to 
the protocol described by Narcís et al. 27. Briefly, spinal cords and skeletal TA muscle samples from WT (n = 3), 
SMN∆7 (n = 3) and nusinersen-treated SMN∆7 (n = 4) mice were lysed at 4 °C in a buffer containing 50 mM 
Tris (pH 8), 150 mM NaCl, 2% Nonidet NP-40, 1 mM  MgCl2, 1 mM dithiothreitol, and 10% glycerol and sup-
plemented with EDTA-free complete protease inhibitor cocktail and PhosphoSTOP (Roche). Samples were soni-
cated and cleared by centrifugation at 14,000 rpm for 10 min at 4 °C. The proteins were separated on 4–20% 
NuPage TG SDS–PAGE gels (Invitrogen) and transferred to nitrocellulose membranes using standard proce-
dures. Mouse monoclonal anti-SMN (diluted 1:500) and rabbit polyclonal anti-Lamin A/C (diluted 1:1,000, 
generously donated by Prof. Gerace) were used. Protein bands were detected with an Odyssey Infrared-Imaging 
System (Li-Cor Biosciences) according to the Odyssey Western-Blotting Protocol. For the quantitative analysis 
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of the blots, ImageJ software was used (U.S. National Institutes of Health, Bethesda, Maryland, USA, https ://
image j.nih.gov/ij).
Statistical analysis. For comparisons among the experimental groups, data were analyzed using GraphPad 
Prism 7 software and PASW Statistics 22 (SPSS, Inc.) packages. Data are expressed as mean ± SD. The statistical 
analysis was assessed by one-way ANOVA or mixed-design two-way ANOVA (Split-Plot ANOVA), followed by 
the Bonferroni post hoc test (SPSS) or Student’s t test (GraphPad). In all cases, differences were considered to be 
statistically significant if p < 0.05.
Received: 27 February 2020; Accepted: 8 June 2020
References
 1. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).
 2. Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265–269. https 
://doi.org/10.1038/ng079 7-265 (1997).
 3. Burghes, A. H. M. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor 
neurons sick?. Nat. Rev. Neurosci. 10, 597–609. https ://doi.org/10.1038/nrn26 70 (2009).
 4. Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy 
gene SMN2. Hum. Mol. Genet. 8, 1177–1183. https ://doi.org/10.1093/hmg/8.7.1177 (1999).
 5. Monani, U. R. et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(−/−) mice 
and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333–339 (2000).
 6. Lorson, C. L. et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 19, 63–66. https ://
doi.org/10.1038/ng059 8-63 (1998).
 7. Cho, S. & Dreyfuss, G. A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. 
Genes Dev. 24, 438–442. https ://doi.org/10.1101/gad.18849 10 (2010).
 8. Feldkötter, M. et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier 
testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70, 358–368. https ://doi.org/10.1086/33862 7 
(2002).
 9. Cuscó, I. et al. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial vari-
ability in siblings. J. Neurol. 253, 21–25. https ://doi.org/10.1007/s0041 5-005-0912-y (2006).
 10. Wirth, B. et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spi-
nal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am. J. Hum. Genet. 64, 1340–1356. 
https ://doi.org/10.1086/30236 9 (1999).
 11. Wirth, B. et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. 
Hum. Genet. 119, 422–428. https ://doi.org/10.1007/s0043 9-006-0156-7 (2006).
 12. Pellizzoni, L., Yong, J. & Dreyfuss, G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298, 
1775–1779. https ://doi.org/10.1126/scien ce.10749 62 (2002).
 13. Meister, G. et al. A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs. Nat. Cell Biol. 3, 
945–949. https ://doi.org/10.1038/ncb11 01-945 (2001).
 14. Matera, A. G. & Wang, Z. A day in the life of the spliceosome. Nat. Rev. Mol. Cell Biol. 15, 108–121. https ://doi.org/10.1038/nrm37 
42 (2014).
 15. Gall, J. G. Cajal bodies: the first 100 years. Annu. Rev. Cell Dev. Biol. 16, 273–300. https ://doi.org/10.1146/annur ev.cellb io.16.1.273 
(2000).
 16. Machyna, M., Heyn, P. & Neugebauer, K. M. Cajal bodies: where form meets function. Wiley Interdiscip. Rev. RNA 4, 17–34. https 
://doi.org/10.1002/wrna.1139 (2013).
 17. Sawyer, I. A., Hager, G. L. & Dundr, M. Specific genomic cues regulate Cajal body assembly. RNA Biol. https ://doi.org/10.1080/15476 
286.2016.12436 48 (2016).
 18. Lafarga, M., Casafont, I., Bengoechea, R., Tapia, O. & Berciano, M. T. Cajal’s contribution to the knowledge of the neuronal cell 
nucleus. Chromosoma 118, 437–443 (2009).
 19. Frey, M. R. & Matera, A. G. RNA-mediated interaction of Cajal bodies and U2 snRNA genes. J. Cell Biol. 154, 499–509. https ://
doi.org/10.1083/jcb.20010 5084 (2001).
 20. Schul, W., van Driel, R. & de Jong, L. Coiled bodies and U2 snRNA genes adjacent to coiled bodies are enriched in factors required 
for snRNA transcription. Mol. Biol. Cell 9, 1025–1036. https ://doi.org/10.1091/mbc.9.5.1025 (1998).
 21. Wang, Q. et al. Cajal bodies are linked to genome conformation. Nat. Commun. 7, 10966. https ://doi.org/10.1038/ncomm s1096 6 
(2016).
 22. Raska, I. et al. Association between the nucleolus and the coiled body. J. Struct. Biol. 104, 120–127 (1990).
 23. Machyna, M. et al. The coilin interactome identifies hundreds of small noncoding RNAs that traffic through Cajal bodies. Mol. 
Cell 56, 389–399. https ://doi.org/10.1016/j.molce l.2014.10.004 (2014).
 24. Trinkle-Mulcahy, L. & Sleeman, J. E. The Cajal body and the nucleolus: “In a relationship” or “It’s complicated”?. RNA Biol. https 
://doi.org/10.1080/15476 286.2016.12361 69 (2016).
 25. Tapia, O. et al. Reorganization of Cajal bodies and nucleolar targeting of coilin in motor neurons of type I spinal muscular atrophy. 
Histochem. Cell Biol. 137, 657–667. https ://doi.org/10.1007/s0041 8-012-0921-8 (2012).
 26. Tapia, O. et al. Cellular bases of the RNA metabolism dysfunction in motor neurons of a murine model of spinal muscular atrophy: 
Role of Cajal bodies and the nucleolus. Neurobiol. Dis. 108, 83–99. https ://doi.org/10.1016/j.nbd.2017.08.004 (2017).
 27. Narcís, J. O. et al. Accumulation of poly(A) RNA in nuclear granules enriched in Sam68 in motor neurons from the SMNΔ7 mouse 
model of SMA. Sci. Rep. 8, 9646. https ://doi.org/10.1038/s4159 8-018-27821 -3 (2018).
 28. Caillet-Boudin, M.-L. et al. Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front. 
Mol. Neurosci. 6, 57. https ://doi.org/10.3389/fnmol .2013.00057 (2014).
 29. Singh, N. K., Singh, N. N., Androphy, E. J. & Singh, R. N. Splicing of a critical exon of human survival motor neuron is regulated 
by a unique silencer element located in the last intron. Mol. Cell Biol. 26, 1333–1346. https ://doi.org/10.1128/MCB.26.4.1333-
1346.2006 (2006).
 30. Hua, Y. et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. 
Hum. Genet. 82, 834–848. https ://doi.org/10.1016/j.ajhg.2008.01.014 (2008).
 31. Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 
1634–1644. https ://doi.org/10.1101/gad.19413 10 (2010).
12
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10738  | https://doi.org/10.1038/s41598-020-67569-3
www.nature.com/scientificreports/
 32. Rigo, F. et al. Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing 
oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46–55. https ://doi.org/10.1124/jpet.113.21240 7 
(2014).
 33. Talbot, K. & Tizzano, E. F. The clinical landscape for SMA in a new therapeutic era. Gene Ther. https ://doi.org/10.1038/gt.2017.52 
(2017).
 34. Bennett, C. F., Krainer, A. R. & Cleveland, D. W. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu. Rev. 
Neurosci. 42, 385–406. https ://doi.org/10.1146/annur ev-neuro -07091 8-05050 1 (2019).
 35. Wood-Allum, C. & Shaw, P. J. Motor neurone disease: a practical update on diagnosis and management. Clin. Med. 10, 252–258 
(2010).
 36. Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. 
Sci. Transl. Med. 3, 72ra18. https ://doi.org/10.1126/scitr anslm ed.30017 77 (2011).
 37. Sahashi, K. et al. TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals. Genes Dev. 26, 1874–1884. 
https ://doi.org/10.1101/gad.19741 8.112 (2012).
 38. Sleigh, J. N. et al. Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular 
atrophy. Hum. Mol. Genet. 23, 855–869. https ://doi.org/10.1093/hmg/ddt47 7 (2014).
 39. Feather-Schussler, D. N. & Ferguson, T. S. A battery of motor tests in a neonatal mouse model of cerebral palsy. J. Vis. Exp. https 
://doi.org/10.3791/53569 (2016).
 40. Dubowitz, V. & Sewry, C. Muscle Biopsy: A Practical Approach (Elsevier, Philadelphia, 2007).
 41. Hua, Y. et al. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic 
mouse models. Genes Dev. 29, 288–297. https ://doi.org/10.1101/gad.25664 4.114 (2015).
 42. Jablonka, S. et al. Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model 
for spinal muscular atrophy type III. Hum. Mol. Genet. 9, 341–346. https ://doi.org/10.1093/hmg/9.3.341 (2000).
 43. Pena, E. et al. Neuronal body size correlates with the number of nucleoli and Cajal bodies, and with the organization of the splicing 
machinery in rat trigeminal ganglion neurons. J. Comp. Neurol. 430, 250–263 (2001).
 44. Lafarga, M., Tapia, O., Romero, A. M. & Berciano, M. T. Cajal bodies in neurons. RNA Biol. https ://doi.org/10.1080/15476 
286.2016.12313 60 (2017).
 45. Liu, Q. & Dreyfuss, G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J. 15, 3555–3565 (1996).
 46. Navascues, J. et al. Targeting SMN to Cajal bodies and nuclear gems during neuritogenesis. Chromosoma 112, 398–409. https ://
doi.org/10.1007/s0041 2-004-0285-5 (2004).
 47. Zhang, Z. et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. 
Cell 133, 585–600. https ://doi.org/10.1016/j.cell.2008.03.031 (2008).
 48. Bäumer, D. et al. Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy. PLoS 
Genet. 5, e1000773. https ://doi.org/10.1371/journ al.pgen.10007 73 (2009).
 49. Lotti, F. et al. An SMN-dependent U12 splicing event essential for motor circuit function. Cell 151, 440–454. https ://doi.
org/10.1016/j.cell.2012.09.012 (2012).
 50. Doktor, T. K. et al. RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of 
U12-dependent introns. Nucleic Acids Res. 45, 395–416. https ://doi.org/10.1093/nar/gkw73 1 (2017).
 51. Jangi, M. et al. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. 
Proc. Natl. Acad. Sci. 114, E2347–E2356. https ://doi.org/10.1073/pnas.16131 81114 (2017).
 52. Zhong, Z. et al. Chondrolectin mediates growth cone interactions of motor axons with an intermediate target. J. Neurosci. 32, 
4426–4439. https ://doi.org/10.1523/JNEUR OSCI.5179-11.2012 (2012).
 53. Bernabò, P. et al. In vivo translatome profiling in spinal muscular atrophy reveals a role for SMN protein in ribosome biology. Cell 
Rep. 21, 953–965. https ://doi.org/10.1016/j.celre p.2017.10.010 (2017).
 54. Peters, A., Palay, S. L. & deF Webster, H. The Fine Structure of the Nervous System: Neurons and Their Supporting Cells 3rd edn. 
(Oxford University Press, New York, 1991).
 55. Casafont, I., Berciano, M. T. & Lafarga, M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 
and PABPN1 in sensory ganglia neurons. Neurotox. Res. 17, 167–178 (2010).
 56. Palanca, A., Casafont, I., Berciano, M. T. & Lafarga, M. Proteasome inhibition induces DNA damage and reorganizes nuclear archi-
tecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol. Life Sci. 71, 1961–1975. https ://doi.org/10.1007/
s0001 8-013-1474-2 (2014).
 57. Hamilton, G. & Gillingwater, T. H. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med. 19, 40–50. https 
://doi.org/10.1016/j.molme d.2012.11.002 (2013).
 58. Chaytow, H., Huang, Y. T., Gillingwater, T. H. & Faller, K. M. E. The role of survival motor neuron protein (SMN) in protein 
homeostasis. Cell Mol. Life Sci. https ://doi.org/10.1007/s0001 8-018-2849-1 (2018).
 59. Porensky, P. N. et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. 
Mol. Genet. 21, 1625–1638. https ://doi.org/10.1093/hmg/ddr60 0 (2012).
 60. Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug 
Discov. 11, 125–140. https ://doi.org/10.1038/nrd36 25 (2012).
 61. Lafarga, M., Andres, M. A., Berciano, M. T. & Maquiera, E. Organization of nucleoli and nuclear bodies in osmotically stimulated 
supraoptic neurons of the rat. J. Comp. Neurol. 308, 329–339. https ://doi.org/10.1002/cne.90308 0302 (1991).
 62. Baltanás, F. C. et al. Purkinje cell degeneration in pcd mice reveals large scale chromatin reorganization and gene silencing linked 
to defective DNA repair. J. Biol. Chem. 286, 28287–28302. https ://doi.org/10.1074/jbc.M111.24604 1 (2011).
 63. Klingauf, M., Stanek, D. & Neugebauer, K. M. Enhancement of U4/U6 small nuclear ribonucleoprotein particle association in Cajal 
bodies predicted by mathematical modeling. Mol. Biol. Cell 17, 4972–4981. https ://doi.org/10.1091/mbc.E06-06-0513 (2006).
 64. Novotný, I. et al. In vivo kinetics of U4/U6·U5 tri-snRNP formation in Cajal bodies. Mol. Biol. Cell 22, 513–523. https ://doi.
org/10.1091/mbc.E10-07-0560 (2011).
 65. Kühn, U. & Wahle, E. Structure and function of poly(A) binding proteins. Biochim. Biophys. Acta 1678, 67–84. https ://doi.
org/10.1016/j.bbaex p.2004.03.008 (2004).
 66. Shan, P. et al. SIRT1 functions as a negative regulator of eukaryotic poly(A)RNA transport. Curr. Biol. 27, 2271-2284.e5. https ://
doi.org/10.1016/j.cub.2017.06.040 (2017).
 67. Hett, A. & West, S. Inhibition of U4 snRNA in human cells causes the stable retention of polyadenylated pre-mRNA in the nucleus. 
PLoS ONE 9, e96174. https ://doi.org/10.1371/journ al.pone.00961 74 (2014).
 68. Novotný, I. et al. SART3-dependent accumulation of incomplete spliceosomal snRNPs in Cajal bodies. Cell Rep. https ://doi.
org/10.1016/j.celre p.2014.12.030 (2015).
 69. Tarabal, O. et al. Mechanisms involved in spinal cord central synapse loss in a mouse model of spinal muscular atrophy. J. Neuro-
pathol. Exp. Neurol. 73, 519–535. https ://doi.org/10.1097/NEN.00000 00000 00007 4 (2014).
 70. Le, T. T. et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice 
with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845–857. https ://doi.org/10.1093/hmg/
ddi07 8 (2005).
 71. Talbot, J. & Maves, L. Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for suscep-
tibility and resistance to muscle disease. Wiley Interdiscip. Rev. Dev. Biol. 5, 518–534. https ://doi.org/10.1002/wdev.230 (2016).
13
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:10738  | https://doi.org/10.1038/s41598-020-67569-3
www.nature.com/scientificreports/
 72. Gokhin, D. S. et al. Tropomodulin isoforms regulate thin filament pointed-end capping and skeletal muscle physiology. J. Cell Biol. 
189, 95–109. https ://doi.org/10.1083/jcb.20100 1125 (2010).
 73. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. 
Methods 25, 402–408. https ://doi.org/10.1006/meth.2001.1262 (2001).
Acknowledgements
The authors wish to thank Raquel García-Ceballos for technical assistance and Alfonso Nieva for video editing. 
We are also grateful to Prof. A. I. Lamond (University of Dundee, UK) for anti-coilin antibody (204.10) and Prof. 
Larry Gerace (The Scripps Research Institute, La Jolla, USA) for anti-LaminA/C antibody. The authors are also 
indebted to Prof. Josep E. Esquerda for critical reading of the manuscript and helpful suggestions. This work was 
supported by the following grants: Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegen-
erativas (CIBERNED, CB06/05/0037) Spain; Instituto de Investigación Sanitaria Valdecilla (IDIVAL, Next-Val 
17/22), Santander, Spain; and Spanish Ministerio de Ciencia, Innovación y Universidades cofinanced by Fondo 
Europeo de Desarrollo Regional (FEDER) (RTI2018-099278-B-I00).
Author contributions
O.T., M.L., M.T.B. and J.C. conceived and designed the experiments. M.T.B., A.P.B., A.M.S., O.T., M.L., and J.C. 
performed the experiments and analyzed the data. O.T., M.L., M.T.B. and J.C.R.R. wrote the paper.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-67569 -3.
Correspondence and requests for materials should be addressed to O.T.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
